Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CureVac ( (CVAC) ) has issued an update.
CureVac N.V. released its unaudited interim condensed consolidated financial statements for the period ending June 30, 2025, revealing a substantial decline in revenue compared to the previous year. The company reported a net loss for the period, highlighting challenges in its financial performance. The financial results indicate a decrease in cash and cash equivalents, reflecting operational difficulties and potential impacts on stakeholders and market positioning.
The most recent analyst rating on (CVAC) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.
Spark’s Take on CVAC Stock
According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.
CureVac demonstrates a strong overall performance led by its solid financial health and attractive valuation. The technical indicators support a bullish outlook, further enhancing the stock’s appeal. While there is room for improvement in revenue growth, the company’s low leverage and efficient cash flow management contribute significantly to its positive score.
To see Spark’s full report on CVAC stock, click here.
More about CureVac
CureVac N.V. is a biotechnology company based in Tübingen, Germany, primarily focused on developing mRNA-based therapies and vaccines. The company operates in the biotechnology industry, with a significant emphasis on innovative medical solutions using mRNA technology.
Average Trading Volume: 1,294,716
Technical Sentiment Signal: Hold
Current Market Cap: $1.24B
Find detailed analytics on CVAC stock on TipRanks’ Stock Analysis page.